BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sureban SM, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E, Ali N, Pantazis P, Westphalen CB, Wang TC, Houchen CW. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 2014;351:151-161. [PMID: 24880079 DOI: 10.1016/j.canlet.2014.05.011] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Chandrakesan P, Weygant N, May R, Qu D, Chinthalapally HR, Sureban SM, Ali N, Lightfoot SA, Umar S, Houchen CW. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. Oncotarget. 2014;5:9269-9280. [PMID: 25211188 DOI: 10.18632/oncotarget.2393] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
2 Sureban SM, Madhoun MF, May R, Qu D, Ali N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA, Houchen CW. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget 2015;6:37200-15. [PMID: 26468984 DOI: 10.18632/oncotarget.5808] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
3 Pereira DM, Gomes SE, Borralho PM, Rodrigues CMP. MEK5/ERK5 activation regulates colon cancer stem-like cell properties. Cell Death Discov 2019;5:68. [PMID: 30774996 DOI: 10.1038/s41420-019-0150-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
4 Bhatt AB, Patel S, Matossian MD, Ucar DA, Miele L, Burow ME, Flaherty PT, Cavanaugh JE. Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling. Biomolecules 2021;11:183. [PMID: 33572742 DOI: 10.3390/biom11020183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Patel O, Roy MJ, Kropp A, Hardy JM, Dai W, Lucet IS. Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1. Commun Biol 2021;4:1105. [PMID: 34545159 DOI: 10.1038/s42003-021-02631-y] [Reference Citation Analysis]
6 Kang C, Kim JS, Kim CY, Kim EY, Chung HM. The Pharmacological Inhibition of ERK5 Enhances Apoptosis in Acute Myeloid Leukemia Cells. Int J Stem Cells 2018;11:227-34. [PMID: 30343550 DOI: 10.15283/ijsc18053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sureban SM, Qu D, Houchen CW. Regulation of miRNAs by agents targeting the tumor stem cell markers DCLK1, MSI1, LGR5, and BMI1. Curr Pharmacol Rep. 2015;1:217-222. [PMID: 26366338 DOI: 10.1007/s40495-014-0006-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
8 Ali S, Dubaybo H, Brand RE, Sarkar FH. Differential Expression of MicroRNAs in Tissues and Plasma Co-exists as a Biomarker for Pancreatic Cancer. J Cancer Sci Ther 2015;7:336-46. [PMID: 26819679 DOI: 10.4172/1948-5956.1000372] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
9 Gomez N, Erazo T, Lizcano JM. ERK5 and Cell Proliferation: Nuclear Localization Is What Matters. Front Cell Dev Biol 2016;4:105. [PMID: 27713878 DOI: 10.3389/fcell.2016.00105] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
10 Riegel K, Yurugi H, Schlöder J, Jonuleit H, Kaulich M, Kirschner F, Arnold-Schild D, Tenzer S, Schild H, Rajalingam K. ERK5 modulates IL-6 secretion and contributes to tumor-induced immune suppression. Cell Death Dis 2021;12:969. [PMID: 34671021 DOI: 10.1038/s41419-021-04257-8] [Reference Citation Analysis]
11 Weygant N, Qu D, May R, Tierney RM, Berry WL, Zhao L, Agarwal S, Chandrakesan P, Chinthalapally HR, Murphy NT. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. Oncotarget. 2015;6:2193-2205. [PMID: 25605241 DOI: 10.18632/oncotarget.3059] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 7.5] [Reference Citation Analysis]
12 Bahrami A, Majeed M, Sahebkar A. Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition. Cell Oncol (Dordr) 2019;42:405-21. [PMID: 30980365 DOI: 10.1007/s13402-019-00442-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
13 Sureban SM, May R, Qu D, Chandrakesan P, Weygant N, Ali N, Lightfoot SA, Ding K, Umar S, Schlosser MJ, Houchen CW. Dietary Pectin Increases Intestinal Crypt Stem Cell Survival following Radiation Injury. PLoS One 2015;10:e0135561. [PMID: 26270561 DOI: 10.1371/journal.pone.0135561] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
14 Ren J, Fu J, Ma T, Yan B, Gao R, An Z, Wang D. LncRNA H19-elevated LIN28B promotes lung cancer progression through sequestering miR-196b. Cell Cycle 2018;17:1372-80. [PMID: 29950144 DOI: 10.1080/15384101.2018.1482137] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
15 Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chem Biol 2020;27:1229-1240.e4. [PMID: 32755567 DOI: 10.1016/j.chembiol.2020.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Ding L, Yang Y, Ge Y, Lu Q, Yan Z, Chen X, Du J, Hafizi S, Xu X, Yao J, Liu J, Cao Z, Weygant N. Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity. Cancers (Basel) 2021;13:5729. [PMID: 34830884 DOI: 10.3390/cancers13225729] [Reference Citation Analysis]
17 Xu R, Shen X, Xie H, Zhang H, Liu D, Chen X, Fu Y, Zhang P, Yang Y, Cheng J, Jiang H. Identification of the canonical and noncanonical role of miR-143/145 in estrogen-deficient bone loss. Theranostics 2021;11:5491-510. [PMID: 33859759 DOI: 10.7150/thno.55041] [Reference Citation Analysis]
18 Kawai S, Fujii T, Kukimoto I, Yamada H, Yamamoto N, Kuroda M, Otani S, Ichikawa R, Nishio E, Torii Y, Iwata A. Identification of miRNAs in cervical mucus as a novel diagnostic marker for cervical neoplasia. Sci Rep 2018;8:7070. [PMID: 29728572 DOI: 10.1038/s41598-018-25310-1] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
19 Gao T, Wang M, Xu L, Wen T, Liu J, An G. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer. J Cancer Res Clin Oncol. 2016;142:2131-2140. [PMID: 27520310 DOI: 10.1007/s00432-016-2218-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
20 Jang DM, Lim HJ, Hahn H, Lee Y, Kim HK, Kim HS. Structural Basis of Inhibition of DCLK1 by Ruxolitinib. Int J Mol Sci 2021;22:8488. [PMID: 34445192 DOI: 10.3390/ijms22168488] [Reference Citation Analysis]
21 Makino S, Takahashi H, Okuzaki D, Miyoshi N, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Mizushima T, Mori M, Doki Y. DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer. Carcinogenesis 2020;41:303-12. [DOI: 10.1093/carcin/bgz157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
22 Abba ML, Patil N, Leupold JH, Allgayer H. MicroRNA Regulation of Epithelial to Mesenchymal Transition. J Clin Med 2016;5:E8. [PMID: 26784241 DOI: 10.3390/jcm5010008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 10.3] [Reference Citation Analysis]
23 Yang M, Ke H, Zhou W. LncRNA RMRP Promotes Cell Proliferation and Invasion Through miR-613/NFAT5 Axis in Non-Small Cell Lung Cancer. Onco Targets Ther 2020;13:8941-50. [PMID: 32982286 DOI: 10.2147/OTT.S255126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Massefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, Becht K, Kim ND, McKeown MR, Roberts JM, Zhang J, Sim T, Alessi DR, Bradner JE, Lizcano JM, Blacklow SC, Qi J, Xu X, Gray NS. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chem Biol 2018;13:2438-48. [PMID: 30102854 DOI: 10.1021/acschembio.7b00638] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
25 Kang XL, He LR, Chen YL, Wang SB. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis. World J Gastroenterol 2020; 26(43): 6853-6866 [PMID: 33268966 DOI: 10.3748/wjg.v26.i43.6853] [Reference Citation Analysis]
26 Kadletz L, Aumayr K, Heiduschka G, Schneider S, Enzenhofer E, Lill C. Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies. Eur Arch Otorhinolaryngol. 2017;274:467-475. [PMID: 27470117 DOI: 10.1007/s00405-016-4227-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
27 Tusa I, Cheloni G, Poteti M, Gozzini A, DeSouza NH, Shan Y, Deng X, Gray NS, Li S, Rovida E, Dello Sbarba P. Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells. Stem Cell Reports. 2018;11:929-943. [PMID: 30245209 DOI: 10.1016/j.stemcr.2018.08.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
28 Weygant N, Ge Y, Qu D, Kaddis JS, Berry WL, May R, Chandrakesan P, Bannerman-Menson E, Vega KJ, Tomasek JJ, Bronze MS, An G, Houchen CW. Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase. Cancer Res 2016;76:4090-9. [PMID: 27287716 DOI: 10.1158/0008-5472.CAN-16-0029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
29 Hoang VT, Yan TJ, Cavanaugh JE, Flaherty PT, Beckman BS, Burow ME. Oncogenic signaling of MEK5-ERK5. Cancer Lett 2017;392:51-9. [PMID: 28153789 DOI: 10.1016/j.canlet.2017.01.034] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
30 Pereira DM, Rodrigues CMP. Targeted Avenues for Cancer Treatment: The MEK5-ERK5 Signaling Pathway. Trends Mol Med 2020;26:394-407. [PMID: 32277933 DOI: 10.1016/j.molmed.2020.01.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
31 Cook SJ, Tucker JA, Lochhead PA. Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish for…. Biochem Soc Trans 2020;48:1859-75. [PMID: 32915196 DOI: 10.1042/BST20190338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
32 Rao CV, Mohammed A. New insights into pancreatic cancer stem cells. World J Stem Cells 2015; 7(3): 547-555 [PMID: 25914762 DOI: 10.4252/wjsc.v7.i3.547] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
33 Lv Y, Song G, Wang R, Di L, Wang J. Doublecortin-like kinase 1 is a novel biomarker for prognosis and regulates growth and metastasis in basal-like breast cancer. Biomedicine & Pharmacotherapy 2017;88:1198-205. [DOI: 10.1016/j.biopha.2017.01.082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
34 Sureban SM, Berahovich R, Zhou H, Xu S, Wu L, Ding K, May R, Qu D, Bannerman-Menson E, Golubovskaya V, Houchen CW. DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers. Cancers (Basel) 2019;12:E54. [PMID: 31878090 DOI: 10.3390/cancers12010054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
35 Wang H, Dai YY, Zhang WQ, Hsu PC, Yang YL, Wang YC, Chan G, Au A, Xu ZD, Jiang SJ, Wang W, Jablons DM, You L. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma. Int J Oncol 2017;51:91-103. [PMID: 28560410 DOI: 10.3892/ijo.2017.4021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
36 Liu Q, Guo X, Que S, Yang X, Fan H, Liu M, Li X, Tang H. LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. Oncotarget. 2017;8:43768-43781. [PMID: 27487126 DOI: 10.18632/oncotarget.10844] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
37 Lotfi Z, Najjary S, Lotfi F, Amini M, Baghbanzadeh A, Rashid DJ, Asl ER, Baradaran B, Mokhtarzadeh A. Crosstalk between miRNAs and signaling pathways involved in pancreatic cancer and pancreatic ductal adenocarcinoma. Eur J Pharmacol 2021;901:174006. [PMID: 33711308 DOI: 10.1016/j.ejphar.2021.174006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Myers SM, Bawn RH, Bisset LC, Blackburn TJ, Cottyn B, Molyneux L, Wong A, Cano C, Clegg W, Harrington RW, Leung H, Rigoreau L, Vidot S, Golding BT, Griffin RJ, Hammonds T, Newell DR, Hardcastle IR. High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors. ACS Comb Sci 2016;18:444-55. [DOI: 10.1021/acscombsci.5b00155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
39 Estaras M, Gonzalez A. Modulation of cell physiology under hypoxia in pancreatic cancer. World J Gastroenterol 2021; 27(28): 4582-4602 [PMID: 34366624 DOI: 10.3748/wjg.v27.i28.4582] [Reference Citation Analysis]
40 Pereira DM, Simões AE, Gomes SE, Castro RE, Carvalho T, Rodrigues CM, Borralho PM. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Oncotarget 2016;7:34322-40. [PMID: 27144434 DOI: 10.18632/oncotarget.9107] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
41 Broner EC, Trujillo JA, Korzinkin M, Subbannayya T, Agrawal N, Ozerov IV, Zhavoronkov A, Rooper L, Kotlov N, Shen L, Pearson AT, Rosenberg AJ, Savage PA, Mishra V, Chatterjee A, Sidransky D, Izumchenko E. Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Front Oncol 2021;11:677051. [PMID: 34336664 DOI: 10.3389/fonc.2021.677051] [Reference Citation Analysis]
42 Stecca B, Rovida E. Impact of ERK5 on the Hallmarks of Cancer. Int J Mol Sci 2019;20:E1426. [PMID: 30901834 DOI: 10.3390/ijms20061426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
43 Wang W, Zhang H, Wang L, Zhang S, Tang M. miR-613 inhibits the growth and invasiveness of human hepatocellular carcinoma via targeting DCLK1. Biochem Biophys Res Commun. 2016;473:987-992. [PMID: 27049311 DOI: 10.1016/j.bbrc.2016.04.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
44 Ito H, Tanaka S, Akiyama Y, Shimada S, Adikrisna R, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Yamaoka S, Tanabe M. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis. PLoS One 2016;11:e0146564. [PMID: 26764906 DOI: 10.1371/journal.pone.0146564] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
45 Gzil A, Zarębska I, Bursiewicz W, Antosik P, Grzanka D, Szylberg Ł. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications. Mol Biol Rep 2019;46:6629-45. [PMID: 31486978 DOI: 10.1007/s11033-019-05058-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
46 Chandrakesan P, May R, Weygant N, Qu D, Berry WL, Sureban SM, Ali N, Rao C, Huycke M, Bronze MS, Houchen CW. Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury. Sci Rep 2016;6:37667. [PMID: 27876863 DOI: 10.1038/srep37667] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
47 Chandrakesan P, Panneerselvam J, Qu D, Weygant N, May R, Bronze MS, Houchen CW. Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells. J Carcinog Mutagen 2016;7:257. [PMID: 27335684 DOI: 10.4172/2157-2518.1000257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
48 Vijai M, Baba M, Ramalingam S, Thiyagaraj A. DCLK1 and its interaction partners: An effective therapeutic target for colorectal cancer. Oncol Lett 2021;22:850. [PMID: 34733368 DOI: 10.3892/ol.2021.13111] [Reference Citation Analysis]
49 Shams R, Asadzadeh Aghdaei H, Behmanesh A, Sadeghi A, Zali M, Salari S, Padrón JM. MicroRNAs Targeting MYC Expression: Trace of Hope for Pancreatic Cancer Therapy. A Systematic Review. Cancer Manag Res 2020;12:2393-404. [PMID: 32308478 DOI: 10.2147/CMAR.S245872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
50 Yang C, Pang X, Chen W, Wang X, Lin G, Chu C, Zhang X, Deng X, Chen X, Liu G. Environmentally responsive dual-targeting nanotheranostics for overcoming cancer multidrug resistance. Science Bulletin 2019;64:705-14. [DOI: 10.1016/j.scib.2019.04.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, Rhim A, Zhao L, Zheng W, Lightfoot S, Pant S, Irvan J, Postier R, Hocker J, Hanas JS, Ali N, Sureban SM, An G, Schlosser MJ, Stanger B, Houchen CW. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PLoS One 2015;10:e0118933. [PMID: 25723399 DOI: 10.1371/journal.pone.0118933] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
52 Patel O, Dai W, Mentzel M, Griffin MD, Serindoux J, Gay Y, Fischer S, Sterle S, Kropp A, Burns CJ, Ernst M, Buchert M, Lucet IS. Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1. Structure 2016;24:1550-61. [PMID: 27545623 DOI: 10.1016/j.str.2016.07.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
53 Leone P, Buonavoglia A, Fasano R, Solimando AG, De Re V, Cicco S, Vacca A, Racanelli V. Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs.J Clin Med. 2019;8. [PMID: 31757094 DOI: 10.3390/jcm8122030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 10.7] [Reference Citation Analysis]
54 Qu D, Weygant N, Yao J, Chandrakesan P, Berry WL, May R, Pitts K, Husain S, Lightfoot S, Li M, Wang TC, An G, Clendenin C, Stanger BZ, Houchen CW. Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer. J Oncol 2019;2019:6402925. [PMID: 31467540 DOI: 10.1155/2019/6402925] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
55 Nishio K, Kimura K, Amano R, Nakata B, Yamazoe S, Ohira G, Miura K, Kametani N, Tanaka H, Muguruma K, Hirakawa K, Ohira M. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma. World J Gastroenterol 2017; 23(31): 5764-5772 [PMID: 28883702 DOI: 10.3748/wjg.v23.i31.5764] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
56 Luiz JPM, Toller‐kawahisa JE, Viacava PR, Nascimento DC, Pereira PT, Saraiva AL, Prado DS, Le Bert M, Giurisato E, Tournier C, Cunha TM, Cunha FQ, Quesniaux V, Ryffel B, Alves‐filho JC. MEK5/ERK5 signaling mediates IL‐4‐induced M2 macrophage differentiation through regulation of c‐Myc expression. J Leukoc Biol 2020;108:1215-23. [DOI: 10.1002/jlb.1ma0520-016r] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
57 Park SJ, Choi YS, Lee S, Lee YJ, Hong S, Han S, Kim BC. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor. Cancer Lett 2016;381:314-22. [PMID: 27543359 DOI: 10.1016/j.canlet.2016.08.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
58 Fan M, Qian N, Dai G. Expression and prognostic significance of doublecortin-like kinase 1 in patients with hepatocellular carcinoma. Oncol Lett 2017;14:7529-37. [PMID: 29344199 DOI: 10.3892/ol.2017.7082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
59 Nguyen CB, Houchen CW, Ali N. APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. Exp Biol Med (Maywood) 2017;242:242-9. [PMID: 27694285 DOI: 10.1177/1535370216672746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
60 Ali N, Nguyen CB, Chandrakesan P, Wolf RF, Qu D, May R, Goretsky T, Fazili J, Barrett TA, Li M, Huycke MM, Bronze MS, Houchen CW. Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism. Sci Rep 2020;10:10578. [PMID: 32601309 DOI: 10.1038/s41598-020-67401-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Ikezono YU, Koga H, Abe M, Akiba J, Kawahara A, Yoshida T, Nakamura T, Iwamoto H, Yano H, Kage M, Sata M, Tsuruta O, Torimura T. High expression of the putative cancer stem cell marker, DCLK1, in rectal neuroendocrine tumors. Oncol Lett 2015;10:2015-20. [PMID: 26622789 DOI: 10.3892/ol.2015.3513] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
62 Takiyama A, Tanaka T, Kazama S, Nagata H, Kawai K, Hata K, Otani K, Nishikawa T, Sasaki K, Kaneko M, Emoto S, Murono K, Takiyama H, Nozawa H. DCLK1 Expression in Colorectal Polyps Increases with the Severity of Dysplasia. In Vivo 2018;32:365-71. [PMID: 29475922 DOI: 10.21873/invivo.11247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Kadletz L, Thurnher D, Wiebringhaus R, Erovic BM, Kotowski U, Schneider S, Schmid R, Kenner L, Heiduschka G. Role of cancer stem-cell marker doublecortin-like kinase 1 in head and neck squamous cell carcinoma. Oral Oncology 2017;67:109-18. [DOI: 10.1016/j.oraloncology.2017.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
64 Kalantari E, Asadi Lari MH, Roudi R, Korourian A, Madjd Z. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas. CBM 2017;20:563-73. [DOI: 10.3233/cbm-170383] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
65 Chandrakesan P, Yao J, Qu D, May R, Weygant N, Ge Y, Ali N, Sureban SM, Gude M, Vega K, Bannerman-Menson E, Xia L, Bronze M, An G, Houchen CW. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. Mol Cancer. 2017;16:30. [PMID: 28148261 DOI: 10.1186/s12943-017-0594-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
66 Cao Z, Weygant N, Chandrakesan P, Houchen CW, Peng J, Qu D. Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment. Cancers (Basel) 2020;12:E3801. [PMID: 33348546 DOI: 10.3390/cancers12123801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
67 Whorton J, Sureban SM, May R, Qu D, Lightfoot SA, Madhoun M, Johnson M, Tierney WM, Maple JT, Vega KJ. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma. Dig Dis Sci. 2015;60:509-513. [PMID: 25283374 DOI: 10.1007/s10620-014-3347-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
68 Patil K, Khan FB, Akhtar S, Ahmad A, Uddin S. The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance. Cancer Metastasis Rev 2021;40:691-720. [PMID: 34453639 DOI: 10.1007/s10555-021-09979-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
69 Shi W, Li F, Li S, Wang J, Wang Q, Yan X, Zhang Q, Chai L, Li M. Increased DCLK1 correlates with the malignant status and poor outcome in malignant tumors: a meta-analysis. Oncotarget 2017;8:100545-57. [PMID: 29246000 DOI: 10.18632/oncotarget.20129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
70 Cicenas J, Zalyte E, Rimkus A, Dapkus D, Noreika R, Urbonavicius S. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers (Basel). 2017;10. [PMID: 29267206 DOI: 10.3390/cancers10010001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 8.4] [Reference Citation Analysis]
71 Ferguson FM, Liu Y, Harshbarger W, Huang L, Wang J, Deng X, Capuzzi SJ, Muratov EN, Tropsha A, Muthuswamy S, Westover KD, Gray NS. Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold. J Med Chem 2020;63:7817-26. [PMID: 32530623 DOI: 10.1021/acs.jmedchem.0c00596] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
72 Zhang S, Zhang G, Guo H. DCAMKL1 is associated with the malignant status and poor outcome in bladder cancer. Tumour Biol 2017;39:1010428317703822. [PMID: 28621231 DOI: 10.1177/1010428317703822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
73 Lv ZD, Kong B, Liu XP, Jin LY, Dong Q, Li FN, Wang HB. miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer. J Cell Mol Med 2016;20:864-73. [PMID: 26820102 DOI: 10.1111/jcmm.12770] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
74 Simões AE, Rodrigues CM, Borralho PM. The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target. Drug Discov Today 2016;21:1654-63. [PMID: 27320690 DOI: 10.1016/j.drudis.2016.06.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
75 Wang Y, Yi J, Liu X. Roles of Dclk1 in the pathogenesis, diagnosis, prognosis and treatment of pancreatic cancer: A review. Expert Rev Gastroenterol Hepatol 2021;:1-7. [PMID: 34937474 DOI: 10.1080/17474124.2022.2020643] [Reference Citation Analysis]
76 Westphalen CB, Quante M, Wang TC. Functional implication of Dclk1 and Dclk1-expressing cells in cancer. Small GTPases 2017;8:164-71. [PMID: 27458755 DOI: 10.1080/21541248.2016.1208792] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]